Mark Patterson

Associate Professor


Dr. Mark Patterson is a graduate of the University of North Carolina-Chapel Hill School of Pharmacy where he earned his Ph.D. in pharmaceutical sciences (2006), and the Yale University School of Public Health where he earned his M.P.H. in chronic disease epidemiology (2002). After receiving his Ph.D., he completed his post-doctoral fellowship in health services research from the Duke Clinical Research Institute and then worked for two years as a health services research analyst at the Research Triangle Institute in Durham, North Carolina.

Dr. Patterson’s specialization areas include: 1) exploring the role of health information technology to improve communication, prescribing patterns, and medication reconciliation within post-acute care settings; 2) managing and building large data sets that are used to build predictive models for health outcomes studies, and 3) facilitating focus groups and conducting qualitative analysis on focus groups transcripts. He was a recent recipient of a 2016 New Investigator Award from the American Association of Colleges of Pharmacy (AACP) on a project entitled “Workflow impact on medication errors occurring during transitions of care between rural facilities.”

As an associate professor at the UMKC School of Pharmacy, Dr. Patterson serves as the course coordinator for a required 3-credit course titled “Economics of Health and Medicine,” a survey course introducing second-year pharmacy students to the theories and applications of microeconomics, pharmacoeconomics and pharmacoepidemiology to pharmacy practice.

Outside the classroom, Dr. Patterson serves as an American Society of Health-System Pharmacists (ASHP) pharmacy post-graduate preceptor for both the Kansas City Veterans Affairs managed care residency PGY1 program and the Veterans Affairs Heartland Network VISN15 pharmacoeconomics residency PGY2 program. His other professional responsibilities include serving on the editorial board of Research in Social and Administrative Pharmacy (RSAP) and the advisory board for the pharmacoeconomics PGY2 program.


  • Health information technology and data sets